Dr Takashi Okamoto MD PhD, Hospital Director, Metabolic Disease Center, Okhotsk-kai Hospital, 793-1, 2nd Ward, Tanno, Kitami, Hokkaido 099-2102, Japan. Email: [email protected]

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Aim: We aimed to determine the feasibility of substituting thiazolidinedione-based therapy for insulin injection therapy in patients with type 2 diabetes.

Methods: Thirty-six subjects (17 men and 19 women) aged 67.8 ± 11.3 years with an average insulin dose of 0.46 ± 0.17 U/kg bodyweight, a duration of insulin therapy of 6.1 ± 8.2 years and an average hemoglobin A1c (HbA1c) of 6.8 ± 1.3% were switched from insulin injection therapy to pioglitazone, glimepiride and voglibose combination therapy.

Results: The number of subjects achieving HbA1c levels of less than 7% at 4 months was 30. The success rate of switch therapy was 83% (30/36). HbA1c was significantly reduced from 6.7 ± 1.3% to 5.9 ± 0.7% at 4 months after the switch (P < 0.01) in 32 patients who completed the planned 4-month study. No adverse effects including heart failure, liver dysfunction or severe hypoglycemia were observed. The insulin dose and the maximum blood glucose on the switch day were significantly lower and the age was significantly higher in the subjects who achieved HbA1c less than 7% at 4 months compared to those who did not (P < 0.05).

Conclusion: Thiazolidinedione-based oral combination therapy may efficiently and safely substitute relatively high-dose insulin injection therapy in patients with type 2 diabetes.

References

1 UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 837–853.
10.1016/S0140-6736(98)07019-6
PubMed Web of Science® Google Scholar
2 Warren R, Frier B. Hypoglycaemia and cognitive function. Diabetes Obes Metab 2005; 7: 493–503.
10.1111/j.1463-1326.2004.00421.x
PubMed Web of Science® Google Scholar
3 Kanda Y, Yamada K, Harada Y et al. Clinical parameters for predicting possibility of insulin therapy withdrawal in patients with type 2 diabetes mellitus. J Jpn Diabetes Soc 2004; 47: 271–275.
Google Scholar
4 Shichiri M, Ohkubo Y, Kishikawa H et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 2): B21–B29.
PubMed Web of Science® Google Scholar
5 Yki-Jarvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004; 35: 1106–1118.
10.1056/NEJMra041001
Web of Science® Google Scholar
6 Kubota N, Terauchi Y, Kubota T et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006; 281: 8748–8755.
10.1074/jbc.M505649200
CAS PubMed Web of Science® Google Scholar
7 DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Int Med 1999; 131: 281–303.
10.7326/0003-4819-131-4-199908170-00008
CAS PubMed Web of Science® Google Scholar
8 Dormandy J, Charbonnel B, Eckland D et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitaAzone Clinical Trial in macroVascular events): a randomized controlled trial. Lancet 2005; 366: 1279–1289.
10.1016/S0140-6736(05)67528-9
CAS PubMed Web of Science® Google Scholar
9 Koshiba K, Nomura M, Nakaya Y et al. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006; 53: 87–94.
10.2152/jmi.53.87
PubMed Google Scholar
10 Marti S, Kolb H, Beuth J et al. Changes in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003; 46: 1611–1617.
10.1007/s00125-003-1238-x
PubMed Web of Science® Google Scholar
11 Inoue K, Ikegami H, Fujisawa T et al. Less frequent body weight gain in elderly type 2 diabetic patients treated with glimepiride. Geriatr Gerontol Int 2003; 3: 56–59.
10.1046/j.1444-1586.2003.00056.x
Google Scholar
12 Saito N, Sakai H, Suzuki S et al. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. J Int Med Res 1998; 26: 219–232.
CAS PubMed Web of Science® Google Scholar
13 Ishida H, Kato S, Nishimura M et al. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. Horm Metab Res 1998; 30: 673–678.
10.1055/s-2007-978956
CAS PubMed Web of Science® Google Scholar
14 The Expert Committee on the Diagnosis and Classification of Diabetes Melittus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183–1197.
10.2337/diacare.20.7.1183
PubMed Web of Science® Google Scholar
15 Kobayashi M, Yamazaki K, Hirano K et al. The status of diabetes control and antidiabetic drug therapy in Japan-A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diabetes Res Clin Pract 2006; 73: 198–204.
10.1016/j.diabres.2006.01.013
PubMed Web of Science® Google Scholar
16 Schmitz O, Charbonnel B, Scheen A. Pioglitazone reduces insulin requirements and improves glycemic control in insulin-treated patients with type 2 diabetes: results from PROactive. Presented as a poster in the European Diabetes Association Conference in 2006.
Google Scholar
17 Stern P, Haffner S. Dyslipidemia in type II diabetes. Diabets Care 1991; 14: 1144–1159.
10.2337/diacare.14.12.1144
PubMed Web of Science® Google Scholar
18 Agardh C, Nilsson-Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982; 5: 322–325.
10.2337/diacare.5.3.322
CAS PubMed Web of Science® Google Scholar
19 Cheng A, Zinman B. Principles of insulin therapy. In: CR Kahn, GC Weir, GL King et al., eds. Joslin's Diabetes Mellitus, 14th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 659–669.
Google Scholar
20 Waugh J, Keating G, Plosker G et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006; 66: 85–109.
10.2165/00003495-200666010-00005
CAS PubMed Web of Science® Google Scholar
21 Langenfeld M, Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation 2005; 111: 2525–2531.
10.1161/01.CIR.0000165072.01672.21
CAS PubMed Web of Science® Google Scholar
22 Watanabe I, Tani S, Anazawa T et al. Pioglitazone on artheriosclerosis in comparison with that of glibencamide. Diabetes Res Clin Pract 2005; 68: 104–110.
10.1016/j.diabres.2004.09.013
CAS PubMed Web of Science® Google Scholar
23 McGuire D, Newby L, Bhapkar M et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004; 147: 246–252.
10.1016/j.ahj.2003.07.024
CAS PubMed Web of Science® Google Scholar
24 Despres J, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–957.
10.1056/NEJM199604113341504
CAS PubMed Web of Science® Google Scholar
25 Wilcox R, Bousser M, Betteridge D et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865–873.
10.1161/01.STR.0000257974.06317.49
CAS PubMed Web of Science® Google Scholar
26 Arai Y, Nakazawa S, Kojima T et al. High adiponectin concentration and its role for longevity in female centenarians. Geriatr Gerontol Int 2006; 6: 32–39.
10.1111/j.1447-0594.2006.00304.x
Google Scholar
27 Kalmijn S, Feskens E, Launer L et al. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995; 38: 1096–1102.
10.1007/BF00402181
CAS PubMed Web of Science® Google Scholar
28 Luchsinger J, Tang M, Shea S et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187–1192.
10.1212/01.WNL.0000140292.04932.87
PubMed Web of Science® Google Scholar
29 Kuusisto J, Koivisto K, Mykkanen L et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997; 315: 1045–1049.
10.1136/bmj.315.7115.1045
CAS PubMed Web of Science® Google Scholar
30 Biessels G, Staekenborg S, Brunner E et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74.
10.1016/S1474-4422(05)70284-2
PubMed Web of Science® Google Scholar
31 Ott A, Stolk R, Van Harskamp F et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53: 1937–1942.
10.1212/WNL.53.9.1937
CAS PubMed Web of Science® Google Scholar
32 Curb J, Rodriguez B, Abbott R et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999; 52: 971–975.
10.1212/WNL.52.5.971
CAS PubMed Web of Science® Google Scholar
33 Luchsinger J, Tang M, Stern Y et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635–641.
10.1093/aje/154.7.635
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume8, Issue4

December 2008

Pages 218-226

Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes

Abstract

References

Citing Literature

References

Related

Information